10 June 2014
Breda, the Netherlands / Ghent, Belgium and White Plains, NY, USA – arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodie [...]
SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS
Ghent, Belgium / Breda, the Netherlands, June 4, 2014 – arGEN-X, a clinical-stage biopharmaceutical company focused on creating [...]
Plans to Submit a New Drug Application to the FDA this Year; Dialogue with EMA continues with intent to seek approval
Leiden, The Netherlands, June 3, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: R [...]
Breda, The Netherlands / Ghent, Belgium, 29 May 2014 – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematologi [...]
Breda, the Netherlands, 28 May 2014 – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune di [...]
Paris, 20 May 2014 : Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments
against proliferative dise [...]
Paris, 19 May 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments against proliferative diseases and [...]
- Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study
Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnost [...]
• Successful completion of CE performance evaluation study covering more than 400 patient samples
• Sales and Marketing Program Underway in Germany, Austria and Switzerland
Holzgerlingen, Germany, M [...]
Re-dosing plans are underway and 96-week data from an open-label extension study of drisapersen for the treatment of DMD presented at the American Academy of Neurology (AAN)
Leiden, The Netherlands, May 1, [...]
10 June 2014
Breda, the Netherlands / Ghent, Belgium and White Plains, NY, USA – arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodie [...]
SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS
Ghent, Belgium / Breda, the Netherlands, June 4, 2014 – arGEN-X, a clinical-stage biopharmaceutical company focused on creating [...]
Plans to Submit a New Drug Application to the FDA this Year; Dialogue with EMA continues with intent to seek approval
Leiden, The Netherlands, June 3, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: R [...]
Breda, The Netherlands / Ghent, Belgium, 29 May 2014 – arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematologi [...]
Breda, the Netherlands, 28 May 2014 – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune di [...]
Paris, 20 May 2014 : Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments
against proliferative dise [...]
Paris, 19 May 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments against proliferative diseases and [...]
- Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study
Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnost [...]
• Successful completion of CE performance evaluation study covering more than 400 patient samples
• Sales and Marketing Program Underway in Germany, Austria and Switzerland
Holzgerlingen, Germany, M [...]
Re-dosing plans are underway and 96-week data from an open-label extension study of drisapersen for the treatment of DMD presented at the American Academy of Neurology (AAN)
Leiden, The Netherlands, May 1, [...]
Follow us
